Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib in MET Altered Brain Tumors
NCT05120960Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tepotinib in brain metastases, glioblastoma (GBM) and non-small cell lung cancer (NSCLC) (5 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Recommended Phase 2 Dose and Intracranial Clinical Benefit. Planned start Feb 2023; status: withdrawn.
02
Drugs
tepotinib
03
Conditions
brain metastasesglioblastoma (GBM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05120960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120960.